Full Text of PDF (697k)
Article in Japanese
Abstract
Topics Series Obstructive Lung Disease
Therapeutics of novel bronchodilators for the treatment of chronic obstructive pulmonary disease
Akifumi Uchida Kentaro Machida Hiromasa Inoue
Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University
ABSTRACT
Inhaled bronchodilators are the mainstay of current treatments for chronic obstructive pulmonary disease (COPD). Ultra-long-acting β2 agonist (ultra-LABA), which has a 24-h bronchodilating effect, rapid onset of action, and superior safety, is similar to tiotropium for the effect of bronchodilation. Ultra-LABA is one of the medicines of first choice for the treatment of COPD. New long-acting muscarinic antagonist (LAMA), which has the possibility of a greater effect for bronchodilation and a more-immediate effect than that of tiotropium, has been approved for marketing authorizations. The LABA/LAMA combination has also been developed and approved. These novel bronchodilators improve lung function, quality of life, and reduce exacerbations, and they may further improve prognosis and modify the long-term decline in lung function.
KEYWORDS
Long-acting β2 agonist (LABA) Long-acting muscarinic antagonist (LAMA) LABA/LAMA combination
AJRS, 3(3): 358-365, 2014
Copyright © The Japanese Respiratory Society All Rights Reserved.